Casdin Capital 13F holdings, Q2 2023
Holdings as of June 30, 2023 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 41 US equity positions worth $1.1bn in its Q2 2023 13F filing. The largest position was BLFS at 14.9% of the reported book, followed by SRPT and RLAY. Against the Q1 2023 filing, it opened 6 new positions, added to 7 and reduced 9 among the top 41 holdings.
What did Casdin Capital own in Q2 2023? Top 41 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2023 |
|---|---|---|---|---|---|---|---|
| 1 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 14.9% | $170.6m | 7,721,535 | 2% | added |
| 2 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 10.2% | $116.2m | 1,015,000 | -12% | reduced |
| 3 | RLAY RELAY THERAPEUTICS INC | Healthcare | 6.6% | $75.3m | 5,998,574 | 5% | added |
| 4 | EQRX INC | 6.4% | $73.5m | 39,527,669 | 0% | held | |
| 5 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 4.6% | $53.2m | 280,000 | 4% | added |
| 6 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 4.5% | $52.0m | 1,275,000 | 0% | held |
| 7 | RVMD REVOLUTION MEDICINES INC | Healthcare | 4.2% | $48.4m | 1,810,000 | 0% | held |
| 8 | EXK EXACT SCIENCES CORP | Basic Materials | 4.1% | $47.0m | 500,000 | -12% | reduced |
| 9 | VERVE THERAPEUTICS INC | 3.9% | $44.3m | 2,360,571 | 11% | added | |
| 10 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 3.6% | $41.4m | 997,017 | 47% | added |
| 11 | 2655787D BLUEPRINT MEDICINES CORP | 3.4% | $39.2m | 620,000 | -7% | reduced | |
| 12 | DNLI DENALI THERAPEUTICS INC | Healthcare | 3.4% | $38.4m | 1,300,000 | 0% | held |
| 13 | TNYA TENAYA THERAPEUTICS INC | 3.3% | $37.5m | 6,381,377 | 5% | added | |
| 14 | CATALENT INC | 2.7% | $31.2m | 720,000 | – | new | |
| 15 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 2.7% | $30.8m | 1,700,000 | 1% | added |
| 16 | SOMALOGIC INC | 2.5% | $29.1m | 12,604,275 | 0% | held | |
| 17 | ILMN ILLUMINA INC | Healthcare | 2.5% | $29.1m | 155,000 | -44% | reduced |
| 18 | MXCT MAXCYTE INC | 1.9% | $21.6m | 4,715,000 | -4% | reduced | |
| 19 | 2SEVENTY BIO INC | 1.8% | $20.5m | 2,023,913 | 0% | held | |
| 20 | 4D MOLECULAR THERAPEUTICS IN | 1.7% | $19.3m | 1,070,000 | 0% | held | |
| 21 | WGS GENEDX HOLDINGS CORP | Healthcare | 1.6% | $18.4m | 3,095,511 | – | new |
| 22 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.6% | $18.2m | 570,000 | 0% | held |
| 23 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 1.4% | $16.3m | 2,520,000 | 0% | held |
| 24 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.9% | $10.1m | 3,206,380 | 0% | held |
| 25 | FATE FATE THERAPEUTICS INC | Healthcare | 0.9% | $9.8m | 2,050,000 | 0% | held |
| 26 | AVIDITY BIOSCIENCES INC | 0.8% | $9.4m | 850,000 | 0% | held | |
| 27 | TWST TWIST BIOSCIENCE CORP | Healthcare | 0.8% | $9.2m | 450,000 | -36% | reduced |
| 28 | PRME PRIME MEDICINE INC | 0.5% | $5.4m | 367,175 | -50% | reduced | |
| 29 | INCY INCYTE CORP | Healthcare | 0.4% | $4.8m | 77,500 | 0% | held |
| 30 | SANA SANA BIOTECHNOLOGY INC | Healthcare | 0.4% | $4.5m | 750,000 | – | new |
| 31 | SG7 SAGE THERAPEUTICS INC | 0.4% | $4.2m | 90,000 | – | new | |
| 32 | GLUE MONTE ROSA THERAPEUTICS INC | 0.3% | $3.5m | 510,882 | 0% | held | |
| 33 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.3% | $3.3m | 1,000,000 | 0% | held |
| 34 | LAB STANDARD BIOTOOLS INC | Healthcare | 0.2% | $2.3m | 1,200,000 | – | new |
| 35 | ABSI ABSCI CORPORATION | 0.2% | $2.1m | 1,368,260 | -75% | reduced | |
| 36 | EXSCIENTIA PLC | 0.1% | $1.3m | 213,900 | 0% | held | |
| 37 | SINGULAR GENOMICS SYSTEMS IN | 0.1% | $1.1m | 1,345,722 | 0% | held | |
| 38 | MIRATI THERAPEUTICS INC | 0.1% | $860.4k | 23,814 | -95% | reduced | |
| 39 | LIANY LIANBIO | 0.0% | $470.6k | 206,415 | 0% | held | |
| 40 | KRONOS BIO INC | 0.0% | $213.0k | 123,839 | 0% | held | |
| 41 | SCILEX HOLDING CO | 0.0% | $131.0k | 23,512 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.